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1. Dosing scheme 
 
3D cardiac microtissues were treated with four anthracyclines (DOX: doxorubicin, EPI: 
epirubicin, IDA: idarubicin, DAU: daunorubicin) at two different doses (THE: therapeutic 
dose, TOX: toxic dose). The dosing scheme is described in Supplementary Table 1. 
 
Supplementary Table 1. Dosing scheme overview. 
 


















0 - 2 h 0,210948 0,601646 0,220762 0,900051 0,004796 0,087217 0,033797 1,074738 
2 - 8 h 0,016106 0,045939 0,012507 0,050995 0,001429 0,022968 0,003623 0,115513 
8 - 24 h 0,008439 0,024081 0,004445 0,018124 0,000941 0,009668 0,000521 0,016609 
24 - 26 h 0,217426 0,620128 0,223587 0,911572 0,005744 0,105634 0,034137 1,085622 
26 - 32 h 0,022025 0,06284 0,01494 0,060921 0,002198 0,037454 0,00393 0,125334 
32 - 48 h 0,013171 0,037611 0,006153 0,025087 0,001527 0,016465 0,000762 0,024283 
48 - 50 h 0,221385 0,631448 0,224894 0,916941 0,006329 0,115424 0,034336 1,091998 
50 - 56 h 0,025699 0,073365 0,016115 0,065701 0,002674 0,045688 0,004115 0,13123 
56 - 72 h 0,016188 0,046262 0,007055 0,028763 0,001886 0,020168 0,000915 0,029173 
72 - 144 h * 0,039025 0,111473 0,028365 0,115649 0,002835 0,037997 0,004697 0,149528 
144 - 146 h 0,227455 0,648925 0,226499 0,923458 0,00712 0,123474 0,034704 1,103816 
146 - 152 h 0,031366 0,089689 0,017592 0,071738 0,00332 0,052668 0,004467 0,142489 
152 - 168 h 0,020879 0,059793 0,00824 0,033595 0,002372 0,023324 0,001228 0,039173 
168 - 170 h 0,22794 0,650331 0,226603 0,923868 0,00717 0,123695 0,034754 1,10543 
170 - 176 h 0,031819 0,091003 0,017689 0,072131 0,00336 0,052869 0,004516 0,144042 
176 - 192 h 0,021255 0,06089 0,008318 0,033915 0,002403 0,023418 0,001273 0,040596 
192 - 194 h 0,22826 0,651272 0,226675 0,92413 0,0072 0,123808 0,034796 1,10676 
194 - 200 h 0,032122 0,09188 0,017752 0,072374 0,003386 0,05297 0,004556 0,145327 
200 - 216 h 0,021506 0,061619 0,008367 0,034113 0,002422 0,023468 0,00131 0,041772 
216 - 218 h 0,228477 0,651882 0,226713 0,924313 0,007219 0,123867 0,03483 1,107861 
218 - 224 h 0,032321 0,092462 0,01779 0,072521 0,003401 0,053025 0,004589 0,14639 
224 - 240 h 0,021673 0,062106 0,008398 0,034238 0,002434 0,023495 0,00134 0,042747 
240 - 312 h * 0,041756 0,119399 0,02897 0,118114 0,003087 0,039272 0,00499 0,158908 
312 - 314 h 0,228813 0,652888 0,226767 0,924539 0,007245 0,123939 0,034918 1,110684 
314 - 320 h 0,032639 0,093402 0,017843 0,07275 0,003422 0,053089 0,004674 0,149117 
320 - 336 h 0,021937 0,062885 0,008441 0,034417 0,00245 0,023527 0,001419 0,045249 
 
*dose determined by averaging over exposure profile for the respective time range 
 
For each treatment, physiologically-based pharmacokinetic models were developed and in 
vivo drug exposure was simulated in the interstitial space of the heart over two weeks of a 
once daily administration. Therapeutic doses were estimated from clinical dosing, whereas 
3 
 
toxic concentrations were computed based on in vitro viability experiments (IC20) in the 
microtissues by reverse dosimetry. From the continuous exposure profiles (Supplementary 
Fig. 2) an experimental setting was derived with three daily media changes for a period of 14 
days (except weekends) mimicking the estimated in vivo PK exposure profiles. Over the 
weekend, spheroids were treated with an average concentration calculated from the PK 
exposure profile. Drugs were administered at the respective concentrations at the beginning 
of the each time range and material for molecular analyses was extracted at the respective 
end of the time range (in bold). 
 
 
2. Experiments and data analyses  
 
Effects of treatments were measured at three different molecular levels (methylome, 
transcriptome and proteome) and at seven time points (2h, 8h, 24h, 72h, 168h, 240h, 336h) 
using three replicate measurements per time point (A, B and C). Additionally, time-matched 
control experiments were performed (DMSO). Supplementary Table 2 lists the different 
experiments. 
 
Supplementary Table 2. Overview of the molecular experiments. In red, outlier experiments 
are marked that didn’t pass the QC procedures and were discarder in further analysis. 
 
A. Methylation experiments* 
Treatment Dose 2h 8h 24h 72h 168h 240h 336h 
DMSO  A B C A B C A B C A B C A B C A B C A B C 
DOX Therapeutic ABC ABC ABC ABC ABC ABC ABC 
DOX Toxic ABC ABC ABC ABC ABC ABC ABC 
EPI Therapeutic A B C A B C A B C A B C A B C A B C A B C 
EPI Toxic A B C A B C A B C A B C A B C A B C A B C 
IDA Therapeutic ABC ABC ABC ABC ABC ABC ABC 
IDA Toxic ABC ABC ABC ABC ABC ABC ABC 
DAU Therapeutic A B C A B C A B C A B C A B C A B C A B C 
DAU Toxic A B C A B C A B C A B C A B C A B C - - - 
* In the case of DOX and IDA treatments the replicate DNA samples were pooled prior to the methylation 
enrichment and sequencing experiments  
B. Transcriptome experiments 
Treatment Dose 2h 8h 24h 72h 168h 240h 336h 
DMSO  A B C A B C A B C A B C A B C A B C A B C 
DOX Therapeutic A B C A B C A B C A B C A B C A B C A B C 
DOX Toxic A B C A B C A B C A B C A B C A B C A B C 
EPI Therapeutic A B C A B C A B C A B C A B C A B C A B C 
EPI Toxic A B C A B C A B C A B C A B C A B C A B C 
IDA Therapeutic A B C A B C A B C A B C A B C A B C A B C 
IDA Toxic A B C A B C A B C A B C A B C A B C A B C 
DAU Therapeutic A B C A B C A B C A B C A B C A B C A B C 







C. Proteome experiments 
Treatment Dose 2h 8h 24h 72h 168h 240h 336h 
DMSO  A B C A B C A B C A B C A B C A B C A B C 
DOX Therapeutic A B C A B C A B C A B C A B C A B C A B C 
DOX Toxic A B C A B C A B C A B C A B C A B C A B C 
EPI Therapeutic A B C A B C A B C A B C A B C A B C A B C 
EPI Toxic A B C A B C A B C A B C A B C A B C A B C 
IDA Therapeutic A B C A B C A B C A B C A B C A B C A B C 
IDA Toxic A B C A B C A B C A B C A B C A B C A B C 
DAU Therapeutic A B C A B C A B C A B C A B C A B C A B C 
DAU Toxic A B C A B C A B C A B C A B C A B C - - - 
 
Different kinds of analysis were performed with the molecular data: 
 
Longitudinal data analysis: This analysis was performed with the transcriptome and 
proteome data with the goal to identify response genes/proteins that have an expression 
profile over time that is different from the control experiments. This analysis was done using 
the R/Bioconductor package MaSigPro and applying a two-step polynomial regression model 
with maximal degree of 2 [1]. For each treatment and dose the respective 21 experiments (7 
time points x 3 replicates) along with the 21 control experiments were summarized into the 
polynomial model and significant deviations were identified according to the respective P-
values (Supplementary Fig. 6 and Methods).  
 
Time-point specific data analysis: This analysis was performed with the transcriptome and 
proteome data with the goal to identify differentially expressed genes/proteins at single time 
points comparing the replicates per time point (3x treatment vs 3x controls) with a statistical 
test (in the case of transcriptome data with DESeq2, in the case of proteome data with 
Student’s t-test; cf. Methods). 
 
Pooled time point analysis: This analysis was performed with the methylation data in order 
to identify differentially methylated regions (DMRs) between AC treatment and controls 
across the seven time points, with prior averaging of the replicates per time point, using the 
QSEA tool (7x treatment vs 7x controls). QSEA transforms the MeDIP-seq enrichment 
counts for each genomic region into a bisulfite-like % methylation value using a Bayesian 








3. Basic data statistics 
 
3.1 Methylome analysis 
QC was performed based on the number of paired-end reads mapped to the reference 
genome, the coverage of the genome sequence and follow-up visual inspection of all 
experiments per treatment group using PCA. This excluded 2 out of 130 (1.5%) experiments 
(IDA, toxic dose, 240h, and IDA, toxic dose, 336h; Supplementary Table 2A). In both cases 
less than 5 Mio reads were available and the experiments were discarded from further 
analysis. 
 
For each treatment and dose differentially methylated regions (DMRs) were identified using 
pooled time point analysis comparing the treatment samples (7; for IDA, toxic only 5) against 
the control samples (7) using QSEA [2]. This led to the following results: 
 
Comparison 




DOX vs DMSO therapeutic dose 6,965,162 45,440 
DOX vs DMSO toxic dose 6,646,623 96,365 
EPI vs DMSO therapeutic dose 8,018,940 158,762 
EPI vs DMSO toxic dose 7,824,113 55,141 
IDA vs DMSO therapeutic dose 6,808,151 61,453 
IDA vs DMSO toxic dose 6,492,202 36,060 
DAU vs DMSO therapeutic dose 9,416,171 174,893 




3.2 Transcriptome analysis 
First, experiments with an insufficient number of mapped paired reads were discarded. 
Additionally, we applied visual inspection using PCA, heatmaps based on expressed genes 
and Cook’s distance measures. Where these measures gave consistent negative results we 
flagged the experiments as ‘outliers’ and excluded them from further analyses. In total 5 out 
of 186 (2.7%) experiments were discarded (Supplementary Table 2B). 
 
Sequences were mapped to the following genomic features: 
 
Total number of genes: 58,219 
Protein-coding genes: 19,817 
Long non-coding RNAs: 15,787 
Small non-coding RNAs: 7,568 
Pseudogenes:  14,637 
Immunoglobulin/T-cell 
receptor gene segments: 410 
 
After mapping, quantification and normalization of the gene expression (Methods) we 
performed longitudinal data analysis using the polynomial regression model in order to 
identify dynamic response genes. The number of dynamic response genes identified by the 




Comparison Number of dynamic response genes 
DOX vs DMSO therapeutic dose 88 
DOX vs DMSO toxic dose 116 
EPI vs DMSO therapeutic dose 127 
EPI vs DMSO toxic dose 158 
IDA vs DMSO therapeutic dose 138 
IDA vs DMSO toxic dose 250 
DAU vs DMSO therapeutic dose 366 
DAU vs DMSO toxic dose 116 
 
Additionally, we performed time-point specific data analysis comparing for each treatment, 
dose and time-point the gene expression measured on the three replicate samples against 
the three replicates of the time-matched control samples. We used DESeq2 for identifying 
differentially expressed genes and corrected the p-values with the Benjamini-Hochberg 





































































3.3. Proteome analysis 
QC was performed on visual inspection using PCA. This excluded 6 out of 186 (3.2%) 
experiments (Supplementary Table 2C). 
Proteins were detected after m/z alignment, RT alignment, peak detection, isotope clustering 
and identification and validation of peptides (Methods). 
 
The following numbers of proteins were detected in the samples and were identified as 
dynamic response proteins with the polynomial regression model: 
 
Experiment 
(Treatment_Dose_TimePoint) Quantified proteins 


































































DAU_TOX_336 not performed 
DMSO_002 1317  
DMSO_008 1390  
DMSO_024 1340  
DMSO_072 1207  
DMSO_168 1344  
DMSO_240 1340  






4. ACT response network construction 
 
We used the PPI network provided by ConsensusPathDB [3,4] as a scaffold and performed 
network propagation with the weights derived from the proteome and transcriptome 
experimental data. The purpose of this analysis was to derive an ACT response network 
describing the most common in vitro responses to the four anthracyclines. This ACT 
response network (Fig. 4) was generated by the following procedure: 
 
1. For each treatment and dose map the dynamic response proteins (Supplementary Data 2) 
to the PPI network and initialize the corresponding nodes with the P-value scores that 
describe the significance of the deviation of the treatment temporal profile from the control 
temporal profile according to Supplementary Fig. 11. Numbers of initialized proteins and 
score densities are shown in the figure. Perform network propagation of the initialized 
weights using random walk with restart [5] and extract the final computed network module 
(genes for the respective modules are shown in Supplementary Data 4). This yields 8 
different computed network modules for the proteome data (4 treatments x 2 doses). 
2. For each treatment and dose map the dynamic response genes (Supplementary Data 3) 
to the PPI network and initialize the corresponding nodes with the P-value scores that 
describe the significance of the deviation of the treatment temporal profile from the control 
temporal profile according to Supplementary Fig. 11. Numbers of initialized genes and score 
densities are shown in the figure. Perform network propagation of the initialized weights 
using random walk with restart [5] and extract the final computed network module (genes for 
the respective modules are shown in Supplementary Data 4). This yields 8 different 
computed network modules for the transcriptome data (4 treatments x 2 doses). 
3. For each treatment and dose map the dynamic response proteins and transcripts to the 
PPI network and initialize the corresponding nodes with the joined P-value scores according 
to Supplementary Fig. 11. Numbers of initialized proteins/genes and score densities are 
shown in the figure. Perform network propagation and extract the final computed network 
module (genes for the respective modules are shown in Supplementary Data 4). This yields 
8 different computed network modules for the integrated data (4 treatments x 2 doses). 
 
As an intermediate result we observed that the final modules derived from the integrated 
data (Supplementary Fig. 12-13) are larger in size (Supplementary Fig. 14) and contain more 
functional information (Supplementary Fig. 15) than the modules derived from proteome data 
only and transcriptome data only. Thus, this approach demonstrates an efficient data 
integration strategy that can easily be extrapolated with further data sets. 
 
We thus continued with the four network modules derived from integrated data 
(Supplementary Data 4), and we constructed the ACT response networks for therapeutic and 
toxic doses respectively from the four individual AC networks computed in step 3 above for 
the respective dose. Since we were interested in common responses at the two doses we 
overlaid the modules for the four treatments and kept only those proteins and their 
interactions that were present in at least 2 of the 4 treatments. We were then particularly 
interested in the effects of the lower therapeutic dose because it is pharmacologically 
relevant and adapted to the clinical dosing in patients. At therapeutic dose this left us with 
175 proteins and their interactions and this network is displayed and discussed in Fig. 4 and 
















































Supplementary Figure 1 Study schema. 3D cardiac microtissues are grown and treated over a time 
period of 14 days with four anthracycline drugs. PBPK modelling is used to infer in vivo drug exposure 
levels at two doses (therapeutic and toxic doses). Omics measurements were done at seven different 
time points (2h, 8h, 24h, 72h, 168h, 240h, 336h). Methylome measurements were used to 
characterize cell identity of cardiac microtissues and to infer effects of AC treatment on 
transcriptional regulation. Proteome and transcriptome measurements were used to characterize 
dynamic cellular responses. Time series data was mapped to a large PPI network in order to integrate 
the data and to identify a common ACT response network across the treatments. The in vitro inferred 
ACT response network was then tested for clinical relevance in cardiomyopathy patient biopsies and 
for physiological relevance on ATP production with sensitivity analysis using an established 











Supplementary Figure 2 In vitro assay dosing. Assay set up with PBPK models and reverse dosimetry. 
The in vitro assay design aims to mimic organ-specific in vivo drug exposure. (a) Dose-response 
experiments for the in vitro cell system are conducted to identify a toxic exposure resulting in a 
reduction of 20 % cell viability. (b) PBPK models are used to estimate the anticipated in vivo dose that 
is needed in a once daily dosing regimen to result in the same exposure via reverse dosimetry. (c) The 
continuous drug exposure profiles are translated into an experimental setting with three daily media 












Supplementary Figure 3 Heart-specific dynamic differentially methylated regions (dDMRs) in 3D 
cardiac microtissues. Ziller et al. [6] have performed whole-genome bisulfite sequencing of 30 
human cell lines of different cell types and developmental stages and identified tissue-specific 
dynamic methylated regions (dDMRs). The dynamic methylome leads to the identification of 
genomic regions that are differentially methylated between fetal heart and other cell lines. We 
selected the lowly (<20%: 16,705 dDMRs) and highly (>80%: 627,864 dDMRs) methylated dDMRs 
from that study and compared their methylation status in the IPSC-derived cardiac microtissues 
(control samples). Blue curve: distribution of lowly methylated dDMRs in cardiac microtissues; red 



































Supplementary Figure 4 Differentially methylated regions in cardiac microtissues. Genomic 
annotation of differentially methylated regions and overall statistics for the different experimental 
conditions. AC-induced methylation values were compared against DMSO controls in order to 
identify differentially methylated regions (DMRs) using the QSEA tool (Lienhard et al., 2017): 42-52% 
of the DMRs fall in intergenic regions. Genic DMRs are mostly in introns (41-43%) with only a 
minority of 2-9% of the DMRs corresponding to exon and 5-8% corresponding to promoter 
sequences (-2kb upstream of the transcription start site). ACs show large differences in methylation 
effects: DAU and EPI induced 3-5 times more changes in methylation than IDA and DOX at 









Supplementary Figure 5 Differentially methylated regions in cardiac microtissues. VENN diagrams 






Time Replicate Control Treatment
C_2h_1 2 1 1 0
C_2h_2 2 1 1 0
C_2h_3 2 1 1 0
C_8h_1 8 2 1 0
C_8h_2 8 2 1 0
C_8h_3 8 2 1 0
C_24h_1 24 3 1 0
C_24h_2 24 3 1 0
C_24h_3 24 3 1 0
C_72h_1 72 4 1 0
C_72h_2 72 4 1 0
C_72h_3 72 4 1 0
C_168h_1 168 5 1 0
C_168h_2 168 5 1 0
C_168h_3 168 5 1 0
C_240h_1 240 6 1 0
C_240h_2 240 6 1 0
C_240h_3 240 6 1 0
C_336h_1 336 7 1 0
C_336h_2 336 7 1 0
C_336h_3 336 7 1 0
Treatment_2h_1 2 8 0 1
Treatment_2h_2 2 8 0 1
Treatment_2h_3 2 8 0 1
Treatment_8h_1 8 9 0 1
Treatment_8h_2 8 9 0 1
Treatment_8h_3 8 9 0 1
Treatment_24h_1 24 10 0 1
Treatment_24h_2 24 10 0 1
Treatment_24h_3 24 10 0 1
Treatment_72h_1 72 11 0 1
Treatment_72h_2 72 11 0 1
Treatment_72h_3 72 11 0 1
Treatment_168h_1 168 12 0 1
Treatment_168h_2 168 12 0 1
Treatment_168h_3 168 12 0 1
Treatment_240h_1 240 13 0 1
Treatment_240h_2 240 13 0 1
Treatment_240h_3 240 13 0 1
Treatment_336h_1 336 14 0 1
Treatment_336h_2 336 14 0 1
Treatment_336h_3 336 14 0 1
AC vs Control design matrix
                                                      
      
Polynomial regression model (degree  2) 
Regression coefficients for
the control group
Regression coefficients for the
specific differences between the
treatment and the control groups
                           
Beta 10.55 1.01 0.00 0.03 0.00 -0.01
P-value 1.25E-45 3.02E-05 NA 1.68E-05 NA 6.63E-07
                           
Beta 10.50 4.98 0.00 0.00 0.00 0.00
P-value 4.95E-56 3.70E-37 NA NA NA NA
                           
Beta 10.45 0.00 0.00 -0.03 0.00 0.00
P-value 3.12E-59 NA NA 3.89E-31 NA NA
Linear treatment effect
Constant (batch) effect
Linear and quadratic treatment effect
a b
c
i: treatment or control (i=1,2) 




Supplementary Figure 6 Longitudinal data analysis using polynomial regression. (a) Design of 
experiments. Every AC treatment at a given dose is measured at seven time points with time-
matched controls with three replicates giving rise to 42 different experiments. (b) Polynomial 
regression model (degree ≤ 2). A two-step procedure is carried out using MaSigPro [1]. (c) Output. 
Fitted regression coefficients and corresponding P-values. Dynamic response proteins/genes are then 
selected based on the regression coefficients 𝛽0 𝑇𝑣𝑠𝐶  𝛽1 𝑇𝑣𝑠𝐶  𝛽2 𝑇𝑣𝑠𝐶  that describe the differences 
between control and the treatment group with respect to the constant, linear and quadratic terms 
respectively (upper and middle panel). Proteins/genes with only constant effects (lower panel) are 
discarded since they likely are influenced by batch effects. Plots show the fitted regression curves for 
the treatment (green) and control (red) with dotted lines and additionally a solid line connecting the 
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Supplementary Figure 7 Protein and gene expression of cardiac troponin T. Time-point specific 
ratios of TNNT2 protein and gene expression compared to controls. Y-axes show log2 fold-changes of 
AC treated and control experiments. X-axes show time points. Replicate values per time point were 
averaged. Large circles correspond to individual time points with significant deviation of treatment 
vs. Controls (Q<0.05). For proteome data Student‘s t-test was used comparing the time-point specific 









Supplementary Figure 8 Visualization of mitochondrial and sarcomeric gene expression changes 
after AC exposure. Exposure to the AC toxic dosing profile. Protein complexes are represented by 
purple ovals with the genes encoding for subunits displayed next it in yellow rectangles. On top of 
each gene, the boxes display the expression change over time, where each box corresponds to a 
specific time point. The fill level of these boxes display the log2 fold change (completely filled boxes: 
log2 fold change < 3), upregulations are depicted in red and downregulations in blue. Significance, 
determined by MagSigPro analysis, is indicated by transparency, where the lightest genes were not 
DEG in any AC, medium transparent are DEG in only 1 AC and not transparent are DEG in at least 2 







Proteome (red): 14 genes
Transcriptome (green): 24 genes
Methylome (blue): 13 genes
 
 
Supplementary Figure 9. Common pathway response of response DMRs, proteins and genes with 
respect to the KEGG pathway „adrenergic signalling in cardiomyocytes“. Pathway components that 
were responding to one or more platforms are highlighted by colored boxes next to the component 
name. Multiple boxes indicate assignment of different genes to the model components. Red: 









T2  T8  T24  T72  T168 T240  T336
 
 
Supplementary Figure 10 Principle of network propagation concept. A large protein-protein 
interaction network (PPI) from 19 different data resources was agglomerated from the 
ConsensusPathDB molecular interaction resource consisting of 10,707 proteins and 114,516 
interactions. In order to weight the proteins according to their information content with respect to 
time-sensitive AC treatment responses we used scores that reflect the dynamic changes of the 
proteins after AC treatment (Supplementary Fig. 11). If the proteins in the network show no 
significant dynamic response they are scored with zero. These initial weights for all proteins in the 
network are summarized to the initial node weight vector, p0. Network propagation then diffuses 
these weights using a random walk with restart procedure and computes a final weight vector p 
which then allows a final reranking of all proteins along with the computation of a subnetwork 
containing the major connected components of the drug response. Network propagation was 
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Supplementary Figure 11 Scoring of network nodes. Left panel: Initial node score distribution for the 
ACs at the different doses for transcriptome data. For each gene/protein, k, the score is computed as 
the sum of the negative log-values of the p-values for the regression coefficients in the respective 
polynomial model. Middle panel: Initial node score distribution for the ACs at the different doses for 
proteome data. Right panel: Initial node scoring distribution for the integrated approach. The 













Supplementary Figure 12 AC-network modules at therapeutic doses. Largest network 
modules computed from integrated proteome and transcriptome data with insulated heat diffusion 
for ACs at therapeutic dose. Nodes were initialized based on the significance of the dynamic changes 
of respective AC treatment compared to DMSO control time series. Node color reflects the 













Supplementary Figure 13 AC-network modules at toxic doses. Largest network modules computed 
from integrated proteome and transcriptome data with insulated heat diffusion for ACs at toxic dose. 
Nodes were initialized based on the significance of the dynamic changes of respective AC treatment 
compared to DMSO control time series. Node color reflects the agglomerated heat (score) after the 
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Supplementary Figure 14 Network module sizes. Sizes of all drug response networks computed from 








































































































































































































































































































































































































































































































Supplementary Figure 15 Functional content of computed network modules. Enrichment of 
functional information for GO categories that are commonly enriched with network modules 
computed from protein data (blue), transcriptome data (red) and integrated data (green). X-axis 
displays the GO terms, Y-axis shows the enrichment score, 𝐸𝑖    log10𝑄𝑖, for each GO term i, 
where Qi  is the Q-value of the enrichment computed with Fisher’s exact test. The upper right plot 









Supplementary Figure 16 Integrated ACT response network module at toxic dose. Integrated drug 
response network from all ACs computed from proteome and transcriptome data with insulated heat 
diffusion at toxic dose from a large protein-protein interaction network. Nodes were initialized based 
on the significance of the dynamic changes of respective AC treatment compared to DMSO control 
time series and for each AC a drug response network was computed (Suppl. Figs. 10,13). Nodes and 
their interactions that appeared in at least 2 of the individual AC networks were integrated. Node 

















Supplementary Figure 17. 48 genes with rare and common variants in DCM and systolic heart failure 
identified by a recent review survey [8] overlap with the integrated response network with 8 genes 









Supplementary Figure 18 Sensitivity analysis of mitochondrial model. (a) Simulated relative change 
in ATP concentration following a macroscopic change in the drug-induced (toxic dose) protein change 
after 7-day exposure. (b) Corresponding protein fold change. (c-f) Absolute values of the ATP 
sensitivities, sorted according to magnitude for doxorubicin, epirubicin, idarubicin, and daunorubicin. 














Supplementary Figure 19 ACT response network proteins cover model components that mostly 
influence ATP concentration. Mitochondrion reaction system with labelled transitions. Colored lines 
indicate model components that have been identified by network modules computed from 
integrated (transcriptome and proteome) in vitro microtissue data and that have significant impact 










Supplementary Figure 20. (a) Simulated fluxes through the subsystems at steady state, as functions 
of time over the course of drug exposure. (ETC flux: mean flux through complexes CI-CIV; TCA flux: 
mean flux through the TCA cycle transitions; ROS flux: total flux of superoxide production given by 
the sum of the fluxes from ETC Complexes I and III.) (b) Comparison of sensitivities of ATP 
concentration with respect to each reaction in the model, following exposure to either the toxic dose 
(vertical axis) or the therapeutic dose (horizontal axis). Sensitivities were calculated by introducing a 
1% change to the reaction activities. The dashed line has unit gradient. Symbols refer to the reactions 
marked in Figure 6a. (c) Sensitivity of ATP concentration to macroscopic changes in reaction activity 
(see Methods), plotted as a function of the fold change in protein density. Symbols refer to the 
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